The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
First-line treatment with ibrutinib in patients with CLL/SLL: Final results from the RESONATE-2 trial
|
The phase III RESONATE-2 trial (NCT01722487) assessed the safety and efficacy of ibrutinib vs chlorambucil in adult patients with untreated CLL/SLL.1 The final 10-year follow-up results of this trial were presented at the SOHO 2024 Annual Meeting by Burger.1
|
| Key learnings |
| At 8 years, the ORR and CR/CRi rates increased to 92% and 36%, respectively, in the ibrutinib arm and remained stable thereafter. |
| At 9 years, PFS rates were higher in the ibrutinib arm compared with the chlorambucil arm (49.7% vs 4.4%), and the OS rate was 68.0% (95% CI, 58.6-75.7). |
| At the time of the final analysis, median OS was not estimable and median PFS was 8.9 years. |
| No new safety signals for ibrutinib were reported during this long-term follow-up. Of the 34 patients who experienced AEs of any grade leading to dose reduction, 28 had all AEs resolved. |
| Data from the RESONATE-2 trial demonstrates the durable clinical efficacy and tolerable safety profile of ibrutinib vs chlorambucil, supporting its use in older adult patients with untreated CLL/SLL, including those with high-risk disease features. |
Abbreviations: AE, adverse event; CI, confidence interval; CLL, chronic lymphocytic leukemia; CR, complete response; CRi, CR with incomplete blood count recovery; ORR, overall response rate; OS, overall survival; PFS, progression free survival; SLL, small lymphocytic lymphoma; SOHO, Society of Hematologic Oncology.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
